4-Hydroxybenzoic acid (4-HBA) and a histone deacetylase 6 (HDAC6) inhibitor could successfully reverse adryamicin (ADM) resistance in human breast cancer cells. This evidence concerns the gene HDAC6 and breast carcinoma.